All News

HOPO Therapeutics completes California Life Sciences FAST Program

The team-focused advising program provided frequent mentoring from experts in a range of regulatory, business development and technical fields Learn about FAST

Plutonium targets immune response, lipid homeostasis, other cellular processes

Organ-specific responses to plutonium exposure have been identified, offering insight into new approaches for pharmaceutical countermeasure design and treatment

Toxicity mechanisms of gadolinium uncovered

Rebecca Abergel, Ph.D. and coworkers at Lawrence Berkeley National Laboratory have determined the ways in which gadolinium disrupts the normal function of cells

New strategic direction for the company announced

Co-founder and CEO Julian Rees, Ph.D. discusses a shift in HOPO’s focus area in last week’s newsletter READ

HOPO Therapeutics joins Pad-13 program at Berkeley SkyDeck

The UC Berkeley-based startup incubator / accelerator provides a vast network of resources, contacts, and guidance to help us achieve our mission

HOPO Therapeutics team awarded 2021 Bakar Fellowship from UC Berkeley

Rebecca Abergel, Ph.D. and Julian Rees, Ph.D. have received a Bakar Fellowship from UC Berkeley to advance the commercial development of our heavy metal chelator 3,4,3,-LI(1,2-HOPO)

Rebecca Abergel granted tenure

Huge congratulations to co-founder Rebecca Abergel, Ph.D. on her promotion to Associate Professor with tenure!